Talecris Still Planning IPO

Talecris Biotherapeutics Holding Corp., a Research Triangle Park, N.C.-based developer of plasma-derived protein therapies, last month filed a pair of amendments to its original IPO filing. Neither amendment disclosed the number of shares to be offered or a price range, but did indicate that the company still plans to go public.

Talecris had originally filed for a $1 billion IPO in 2007, but later agreed to be acquired by Australia’s CSL Ltd. for $3.1 billion. That deal was scuttled by anti-trust regulators. Talecris is controlled by Cerberus Management and Ampersand Ventures. www.talecris.com

Leave a Reply

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget